denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Clinical Trials, Biological therapies, Cytokine Release Syndrome, Antibody Therapy, Clinical Practice (Health Services and Quality), Non-Biological therapies, Neurotoxicity, Bispecific Antibody Therapy, Workforce, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Plasma Cell Disorders, Combination therapy, Diversity, Equity, and Inclusion (DEI) , drug development, Diseases, Therapies, immunology, Immunotherapy, Adverse Events, Lymphoid Malignancies, Biological Processes, Monoclonal Antibody Therapy
Description:
The importance of the immune system in multiple myeloma (MM) treatment was first demonstrated in patients undergoing allogeneic stem cell transplant. Unfortunately this early immunotherapy approach was significantly limited by transplant-associated morbidity and mortality. Since antibody-based immunotherapies have emerged as an important aspect of therapy for all MM patients, positively impacting survival. Novel antibody formats, chimeric antigen receptor (CAR) T-cells and non-cellular immune approaches demonstrate the vast possibilities for further innovation and offer new hope in a yet incurable disease.
Dr. Paula Rodriguez Otero will outline the current state of approved BCMA-directed CAR T-cell therapy in advanced MM as well as future developments focused on optimizing patient care and novel CAR designs. BCMA-directed CAR T-cells have shown unprecedented efficacy in heavily pre-treated MM leading to the approval of two BCMA CAR-T cell products. Still, no plateau is seen in the survival curves and relapses continue to occur. Therefore, further improvement is needed. Potential strategies including earlier use in MM as well as next generation CARs, to further augment efficacy will be discussed.
Dr. Suzanne Trudel will discuss the evolving therapeutic landscape of antibodies in MM including the use of naked antibodies in the frontline setting. Advances in antibody design have resulted in antibodies with improved properties to maximize efficacy that includes bispecific antibodies and antibody drug conjugates (ADCs). Belantamab mafodotin is an approved ADC-targeting BCMA, while BMCA-targeting bispecifics will soon be approved for commercial use. The efficacy of these novel antibodies in advanced MM, as well as the unique safety considerations of these agents will be discussed.
Dr. Sarah Holstein will provide an overview of non-cellular immunotherapy approaches to add to the MM therapeutic armamentarium. While CARs and novel antibodies are rapidly being developed, there continues to be a focus on non-cellular therapies that harness the immune system. The class of drugs that target the cereblon complex has expanded beyond the original immunomodulatory drugs (IMiDs) to include next-generation cereblon E3 ligase modulators (CELMoDs). Ongoing studies are evaluating the potential of adding novel agents including repurposed drugs to IMiDs/CELMoDs. Other novel immunotherapies under development include immunocytokines, immunotoxins and NK cell activators/engagers.
The importance of the immune system in multiple myeloma (MM) treatment was first demonstrated in patients undergoing allogeneic stem cell transplant. Unfortunately this early immunotherapy approach was significantly limited by transplant-associated morbidity and mortality. Since antibody-based immunotherapies have emerged as an important aspect of therapy for all MM patients, positively impacting survival. Novel antibody formats, chimeric antigen receptor (CAR) T-cells and non-cellular immune approaches demonstrate the vast possibilities for further innovation and offer new hope in a yet incurable disease.
Dr. Paula Rodriguez Otero will outline the current state of approved BCMA-directed CAR T-cell therapy in advanced MM as well as future developments focused on optimizing patient care and novel CAR designs. BCMA-directed CAR T-cells have shown unprecedented efficacy in heavily pre-treated MM leading to the approval of two BCMA CAR-T cell products. Still, no plateau is seen in the survival curves and relapses continue to occur. Therefore, further improvement is needed. Potential strategies including earlier use in MM as well as next generation CARs, to further augment efficacy will be discussed.
Dr. Suzanne Trudel will discuss the evolving therapeutic landscape of antibodies in MM including the use of naked antibodies in the frontline setting. Advances in antibody design have resulted in antibodies with improved properties to maximize efficacy that includes bispecific antibodies and antibody drug conjugates (ADCs). Belantamab mafodotin is an approved ADC-targeting BCMA, while BMCA-targeting bispecifics will soon be approved for commercial use. The efficacy of these novel antibodies in advanced MM, as well as the unique safety considerations of these agents will be discussed.
Dr. Sarah Holstein will provide an overview of non-cellular immunotherapy approaches to add to the MM therapeutic armamentarium. While CARs and novel antibodies are rapidly being developed, there continues to be a focus on non-cellular therapies that harness the immune system. The class of drugs that target the cereblon complex has expanded beyond the original immunomodulatory drugs (IMiDs) to include next-generation cereblon E3 ligase modulators (CELMoDs). Ongoing studies are evaluating the potential of adding novel agents including repurposed drugs to IMiDs/CELMoDs. Other novel immunotherapies under development include immunocytokines, immunotoxins and NK cell activators/engagers.